Journal article icon

Journal article

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Abstract:

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with certolizumab pegol that was first published in 2011. OBJECTIVES: To assess the clinical benefits and harms of certolizumab pegol (CDP870) in patients with RA who have not responded well to conventi...

Expand abstract

Actions


Access Document


Authors


Ruiz Garcia, V More by this author
Jobanputra, P More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Primary Care Health Sciences, PHC-EBM
Cabello, JB More by this author
Vela Casasempere, P More by this author
Expand authors...
Journal:
The Cochrane database of systematic reviews
Volume:
9
Pages:
CD007649
Publication date:
2014
DOI:
EISSN:
1469-493X
URN:
uuid:bebb29b0-bc5c-473b-94c9-b01c587d84be
Source identifiers:
139031
Local pid:
pubs:139031
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP